Abstract 1191P
Background
Breast cancer is the most common type of malignancy and the leading cause of cancer-related death among women. Among its risk factors, excess body fat is one of the most remarkable. Body Mass Index (BMI) is the most frequently used indice to determine body fat percentage. However, other estimators also exist, such as Clinica Universidad de Navarra – Body Adiposity Estimator (CUN-BAE). Our aim is to compare the attributable fraction of body fat among postmenopausal women with breast cancer by comparing BMI versus CUN-BAE.
Methods
We performed a case-control study by using the MCC-Spain database. It is a population multi-case control study that includes high incidence tumours in Spain. We calculated the BMI and CUN-BAE after dividing the total number of cases into four respective categories. Lastly, we compared the population attributable fraction of body fat with both indices.
Results
We included a total of 2176 women, 1143 (52.52%) in the control group and 1033 (47,47%) cases of women with breast cancer. The body fat distribution data for the different BMI groups in cases and controls were the following: 36,5% vs 45,6%, 38,8% vs 34,6%, 18,5 vs 14,7%,6 % vs 5%, respectively. The data for CUN-BAE in cases and control were: 14% vs 20%, 31,7% vs 33%, 33,5% vs 29%, 2 % vs 17%, respectively. (Table). As a result, the population attributable fraction was 28,6% by using the BMI and 46,2% in CUN-BAE.
Conclusions
The increase in body fat determined by CUN-BAE, after adjusting it based on the menopausal status and hormonal factors, has shown to directly correlate with an increased risk of breast cancer. We conclude that CUN-BAE is a more precise measure than BMI. Table. Table: 1191P
| BMI PostMENOPAUSAL women | CASES % | CASES n | CONTROLS % | CONTROLS n | ODDS RATIO | Prevalence | PR/OR | Population attributable fraction | |
| <25 | 0,368 | 380 | 0,456 | 521 | 1,000 | 0,368 | 0,368 | ||
| 25-29,9 | 0,389 | 402 | 0,346 | 395 | 1,712 | 0,389 | 0,227 | ||
| 30,0-34,9 | 0,182 | 188 | 0,147 | 168 | 2,184 | 0,182 | 0,083 | ||
| >=35 | 0,061 | 63 | 0,0516 | 59 | 1,823 | 0,061 | 0,033 | ||
| Total | 1 | 1033 | 1 | 1143 | 0,712 | 0,288 | |||
| CUNBAE | |||||||||
| <35 | 0,1588 | 164 | 0,2056 | 235 | 1,000 | 0,159 | 0,159 | ||
| 35,0-39,9 | 0,3136 | 324 | 0,3316 | 379 | 1,486 | 0,314 | 0,211 | ||
| 40,0-44,9 | 0,3291 | 340 | 0,2896 | 331 | 2,392 | 0,329 | 0,138 | ||
| >=45 | 0,1985 | 205 | 0,1732 | 198 | 2,726 | 0,199 | 0,073 | ||
| Total | 1 | 1033 | 1 | 1143 | 0,580 | 0,420 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.